摘要
全组共1055例Ⅲ期肺癌手术切除,5、10年生存率分别为22.1％和15.3％,T_3N_0M_0预后好,5、10年生存率分别为41％和29.9％,虽N_2组预后较差,但是5,10年生存率仍有15.7％和9.1％,优于其它疗法。我们认为对纵隔淋巴结转移数少,及手术技术允许的N_2可以切除,但对食道旁、肺下韧带及隆突下淋巴结转移的手术应从严。Ⅲ期小细胞肺癌的长期生存率虽低,但和以往相比有所提高,可能和近年开展多方法学治疗有关,生存3年无病,可望根除。腺癌术后3年生存率仍不断下降,10年生存率仅为5年之半数,提示重视于血道、淋巴道内微转移灶之存在的重要性。
1055 cases of stage Ⅲ lung cancer were treated surgically with 5yr and 10yr survival rates of 22.1% and 15.3%, respectively. It shows that a selective surgical treatment is preferable for partial stage Ⅲ lung cancer, especially in cases with T_3N_0N_0. Its 5yr and 10yr survival rates were 41% and 29.9%. Though a poorer prognosis was seen in the N_2 group, its 5yr and 10yr survival rates were 15.7% and 9.1%, still better than those treated with other therapies. We think surgery might indicate for the N_2 group with fewer lymphonodes and little metastasis to the lymphonodes with the exception of paraoesophageal, subpulmonary ligamental or subaortic lymphonodes. Though stage Ⅲ SCLC has the poorest 3-5-10-year survival rates of only 8.6%, 7.2% and 7.2%, respectively, yet progress has been made. If a stage Ⅲ SCLC case survives up to 3 years without recurrence, a thorough cure might be expected. The survival rate of adenocarcinoma still shows a declining tendency. The 10yr survival rate is only half of the 5yr rate, suggesting a potential micrometastasis in the blood and lympha stream should be considered.
出处
《实用肿瘤杂志》
CAS
北大核心
1993年第1期10-13,共4页
Journal of Practical Oncology
关键词
肺肿瘤
外科手术
stage Ⅲ lung cancer surgery
